查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
遗传性血管性水肿市场：按药物类别、给药途径、分销渠道和地区 - 规模、份额、前景和机会分析，2022-2030
市场调查报告书
商品编码
1110121

遗传性血管性水肿市场：按药物类别、给药途径、分销渠道和地区 - 规模、份额、前景和机会分析，2022-2030

Hereditary Angioedema Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 175 Pages | 商品交期: 2-3个工作天内

价格
简介目录

遗传性血管性水肿 (HAE) 的特征是由常染色体显性基因突变引起的急性皮肤和黏膜水肿。目前的治疗方法包括静脉注射、皮下注射和口服 HAE 药物。这种疾病会导致肿胀，尤其是面部和呼吸道肿胀，以及腹部痉挛。气道肿胀会导致阻塞，这可能是一种非常严重的并发症。这些症状是由于某些蛋白质的缺乏或功能障碍导致的，这些蛋白质有助于保持液体流过非常小的血管（毛细血管）。这种疾病的严重程度在受影响的个体之间差异很大。皮肤肿胀会导致疼痛、残疾和毁容，但通常不是危险的和暂时的。世界过敏组织 (WAO) 制定了使用不同类别药物的指南，包括酯□抑製剂和激□释放□抑製剂，这些药物被批准用于治疗遗传性血管性水肿。 HAE 可能由 C1NH 基因（也称为 SERPING1 基因）或 F12 基因中的基因改变（致病变异）引起。也有原因不明的情况。

市场动态

主要参与者将加入战略联盟和收购，以开发和扩展其遗传性血管性水肿 (HAE) 产品组合，并加快各自的管道以加快产品交付速度。我们正在招聘。例如，2018年1月，设计和开髮用于遗传性血管性水肿（HAE）和骨化性纤维发育不良（FOP）等罕见疾病的小分子药物的BIOCRYST PHARMACEUTICALS, INC.与Biopharmaceutical公司Idera Pharmaceuticals合併，创建了一个新的罕见病。疾病公司。两家公司的合併将创建一个全面且可持续的罕见病专业，利用集体技能、内部专业知识和综合资产开发一系列罕见病的治疗方法，包括预计将出现的生物技术公司的遗传性血管性水肿。

本研究的主要特点

  • 它对全球遗传性血管性水肿市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2030 年）的市场规模和復合年增长率 (CAGR%)。
  • 解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
  • 该研究还提供了有关市场驱动因素、抑制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
  • 基于公司亮点、产品组合、关键亮点、财务业绩和战略等参数的全球遗传性血管性水肿市场主要参与者的概况。
  • 本研究涵盖的主要公司包括 CSL Behring、武田製药有限公司、Pharming、BIOCRYST PHARMACEUTICALS, INC.、Ionis Pharmaceuticals, Inc.、Attune Pharmaceuticals、Arrowhead Pharmaceuticals, Inc.、Adverum Biotechnologies, Inc.、 KalVista Pharmaceuticals、CENTOGENE N.V.和赛诺菲
  • 本报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。奖品
  • 全球遗传性血管性水肿市场报告面向行业内的各种利益相关者，包括投资者和供应商、产品製造商、分销商、新进入者和财务分析师。
  • 利益相关者可以通过用于分析全球遗传性血管性水肿市场的各种策略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

  • 调查目的
  • 先决条件
  • 缩写说明

第2章市场展望

  • 举报内容
    • 市场定义和范围
  • 执行摘要
    • 市场快照：按药物类别
    • 按管理途径划分的市场概况
    • 市场快照：按分销渠道
    • 市场概况：按地区划分
  • 连贯的机会图 (COM)

第 3 章市场动态、法规和趋势分析

  • 市场动态
    • 驱动程序
    • 限制因素
    • 市场机会
  • 主要亮点
  • 管道分析
  • 监管准则
  • 流行病学

第 4 章全球遗传性血管性水肿市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 对供需的影响
  • COVID-19 的流行病学
  • COVID-19 对整个医疗保健市场的影响

第 5 章全球遗传性血管性水肿市场：按药物类别，2017-2030 年

  • C1酯□抑製剂
  • 激□释放□抑製剂
  • 缓激□受体
  • 减少雄激素
  • 其他

第 6 章按管理途径划分的全球遗传性血管性水肿市场：2017-2030 年

  • 皮下给药
  • 静脉给药
  • 口服给药

第 7 章。按分销渠道划分的全球遗传性血管性水肿市场：2017-2030 年

  • 医院药房
  • 零售药房
  • 电子商务

第 8 章全球遗传性血管性水肿市场：2017-2030 年各地区

  • 北美
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地区
  • 欧洲
  • 英国
  • 德国
  • 意大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 东盟
  • 澳大利亚
  • 韩国
  • 其他亚太地区
  • 中东
  • 海合会
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中非
  • 南非

第 9 章竞争格局

  • CSL Behring
  • Takeda Pharmaceutical Company Limited.
  • Pharming
  • BIOCRYST PHARMACEUTICALS, INC.
  • Ionis Pharmaceuticals, Inc.
  • Attune Pharmaceuticals
  • Arrowhead Pharmaceuticals, Inc.
  • Adverum Biotechnologies, Inc.
  • KalVista Pharmaceuticals
  • CENTOGENE N.V.
  • Sanofi

第10章 章节

  • 调查手法
  • 关于出版社
简介目录
Product Code: CMI1292

Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The disease causes swelling particularly of the face and airways and abdominal cramping. Swelling of the airway may lead to obstruction, a potentially very serious complication. These symptoms develop as the result of deficiency or improper functioning of certain proteins that help to maintain the normal flow of fluids through very small blood vessels (capillaries). The severity of the disease varies greatly among affected individuals. Skin swelling can cause pain, dysfunction, and disfigurement, although it is generally not dangerous and is temporary. The World Allergy Organization (WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein inhibitors and other drugs approved to treat hereditary angioedema. HAE may be caused by genetic changes (pathogenic variants) in the C1NH gene (also called the SERPING1 gene) or in the F12 gene. In some cases, the cause is not known.

Market Dynamics

Key players are adopting strategic collaborations and acquisitions for development and expansion of the hereditary angioedema (HAE) portfolio and to accelerate respective pipelines for faster delivery of products. For instance, In January 2018, BIOCRYST PHARMACEUTICALS, INC., a company that designs and develops small molecule medicines for rare diseases such as hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP), and Idera Pharmaceuticals, a clinical-stage biopharmaceutical company, merged to create a new rare-disease company. The combination of two companies is expected to capitalize on the collective skills sets, internal expertise and combined assets to create a comprehensive, sustainable rare disease-focused biotechnology company developing treatments for various rare diseases including hereditary angioedema.

Key features of the study:

  • This report provides in-depth analysis of the global hereditary angioedema market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hereditary angioedema market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include CSL Behring, Takeda Pharmaceutical Company Limited., Pharming, BIOCRYST PHARMACEUTICALS, INC., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, CENTOGENE N.V., and Sanofi
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary angioedema market

Detailed Segmentation:

  • Global Hereditary Angioedema Market, By Drug Class:
    • C1 Esterase Inhibitor
    • Kallikrein Inhibitor
    • Bradykinin Receptor
    • Attenuated Androgens
    • Others
  • Global Hereditary Angioedema Market, By Route of Administration:
    • Subcutaneous
    • Intravenous
    • Oral
  • Global Hereditary Angioedema Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • e-Commerce
  • Global Hereditary Angioedema Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • CSL Behring
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Takeda Pharmaceutical Company Limited.
    • Pharming
    • BIOCRYST PHARMACEUTICALS, INC.
    • Ionis Pharmaceuticals, Inc.
    • Attune Pharmaceuticals
    • Arrowhead Pharmaceuticals, Inc.
    • Adverum Biotechnologies, Inc.
    • KalVista Pharmaceuticals
    • CENTOGENE N.V.
    • Sanofi

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Key Highlights
  • Pipeline Analysis
  • Regulatory Guidelines
  • Epidemiology

4. Global Hereditary Angioedema Market - Impact of Coronavirus (Covid-19) Pandemic

  • Impact on Supply and Demand
  • COVID-19 Epidemiology
  • COVID-19 Impact on overall healthcare market

5. Global Hereditary Angioedema Market, By Drug Class, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • C1 Esterase Inhibitor
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Kallikrein Inhibitor
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Bradykinin Receptor
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Attenuated Androgens
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Hereditary Angioedema Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Subcutaneous
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Intravenous
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Hereditary Angioedema Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • e-Commerce
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Hereditary Angioedema Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • UK
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • CSL Behring
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Takeda Pharmaceutical Company Limited.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pharming
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • BIOCRYST PHARMACEUTICALS, INC.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ionis Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Attune Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Arrowhead Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Adverum Biotechnologies, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • KalVista Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CENTOGENE N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Section

  • Research Methodology
  • About Us